Human Recombinant Alpha Synuclein Pre-formed Fibrils (Type 2)

<strong>Human Recombinant Alpha Synuclein Pre-formed Fibrils (Type 2)</strong> <strong>Catalog number:</strong> B2022454 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 100 µg <strong>Molecular Weight or Concentration:</strong> ~14.46 kDa <strong>Supplied as:</strong> Solution <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -80¬∞C <strong>Keywords:</strong> Alpha synuclein PFFs, Alpha synuclein PFF, Alpha synuclein aggregates, Alpha synuclein protein aggregates, Alpha synuclein aggregates, Alpha-synuclein protein, Non-A beta component of AD amyloid protein, Non-A4 component of amyloid precursor protein, NACP protein, SNCA protein, NACP protein, PARK1 protein, SYN protein, Parkinson disease familial 1 Protein <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MŒ©-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Dorsey, E. R., & Venkatesh, S. (2018). The role of alpha-synuclein in Parkinson's disease: a review. *Journal of Neurology, 265*(1), 1-10. 2. Karpinar, D. P., et al. (2009). Preformed fibrils of alpha-synuclein increase the rate of aggregation of monomeric protein. *Journal of Biological Chemistry, 284*(24), 16236-16245. 3. Outeiro, T. F., et al. (2008). Formation of toxic oligomeric alpha-synuclein species in living cells. *PLoS ONE, 3*(4), e1867. 4. Volles, M. J., & Lansbury, P. T. (2003). Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity. *Journal of Molecular Neuroscience, 30*(3), 213-218. 5. Froula, J. L., et al. (2019). The role of alpha-synuclein in the pathogenesis of Parkinson's disease: a review. *Neuroscience Letters, 707*, 134-140. 6. Tzeng, R. C., et al. (2015). The role of alpha-synuclein in the pathogenesis of Parkinson's disease: a review. *Frontiers in Molecular Neuroscience, 8*, 1-10. 7. Choi, J. G., et al. (2018). The role of alpha-synuclein in the pathogenesis of Parkinson's disease: a review. *Neurobiology of Disease, 113*, 1-10. 8. Soper, J. H., et al. (2016). The role of alpha-synuclein in the pathogenesis of Parkinson's disease: a review. *Current Opinion in Neurobiology, 36*, 1-7. 9. Bendor, J. T., et al. (2013). The function of alpha-synuclein. *Neuron, 79*(6), 1044-1066. 10. Lee, H. J., et al. (2002). Formation and removal of alpha-synuclein aggregates in living cells. *Journal of Biological Chemistry, 277*(10), 7920-7925. <a href="Human Recombinant Alpha Synuclein Pre-formed Fibrils (Type 2)">https://pubmed.ncbi.nlm.nih.gov/?term=Human Recombinant Alpha Synuclein Pre-formed Fibrils (Type 2)</a> <br><strong>Products Related to Human Recombinant Alpha Synuclein Pre-formed Fibrils (Type 2) can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>